MARKET COMPOSITE
Market TodayThemes and Stocks SummaryThematic Stock SearchDaily Refresh Schedule
BYSI - BeyondSpring Inc
$13.26
0.28(2.16%)9:00:01 PM 3/1/2021
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin that is in late stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC) for the prevention of high and intermediate risk chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a programmed cell death protein 1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody to treat small cell lung cancer; and death protein 1 or programmed death-ligand 1, an antibodies and radiation or chemotherapy for the treatment of multiple cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform using ubiquitin mediated protein degradation pathway. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

No summary
Related Topics
leak data

Related Topics

Peers

Related Peers

Stock news

    01/11/2021BYSI
    Benzinga's Top Upgrades, Downgrades For January 11, 2021

    Upgrades * Seaport Global upgraded the previous rating for Huntsman Corp (NYSE:HUN) from Neutral to Buy. In the third quarter, Huntsman showed an EPS of $0.32, compared to $0.41 from the year-ago quarter. The current stock performance of Huntsman shows a 52-week-high of $28.94 and a 52-week-low of $12.23. Moreover, at the end of the last trading period, the closing price was at $28.40. * According to Raymond James, the prior rating for Willis Towers Watson PLC (NASDAQ:WLTW) was changed from M...

    12/29/2020BYSI
    Tuesday’s 10 Notable Market Movers in the Limelight

    U.S. stocks continued their rally on Tuesday morning after the U.S. government approved the new Covid-19 relief package. At 12:17 p.m. ET, the S&P 500 Index rose 2.69 points, or 0.07 percent, the Nasdaq Composite Index fell 37.62 points, or 0.29 percent, and Dow Jones Industrial Average decreased 7.66 points or 0.03 percent. The surge […]

    12/29/2020BYSI
    UPDATE -- BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021

    NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference (JPM) on Thursday, January 14, 2021 at 7:30 a.m. ET, and will be available for 1x1 meetings. The BeyondSpring leadership team also will be available for one-on-one meetings ...

    12/29/2020BYSI
    BeyondSpring to Present at the J.P. Morgan Healthcare Conference on January 14, 2021

    NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that CEO Dr. Lan Huang is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference (JPM) on Thursday, January 14, 2021 at 7:30 a.m. ET, and will be available for 1x1 meetings. The BeyondSpring leadership team also will be available for one-on-one meetings ...

    12/17/2020BYSI
    BeyondSpring Announces the Appointment of Dr. Jeffrey Vacirca to its Board of Directors

    NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherapy-...

    12/10/2020BYSI
    BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium

    \- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC < 0.1 x 10E9 cells/L) by 53 % vs. pegfilgrastim alone \- The plinabulin + pegfilgrastim combination reduces the odds of having febrile neutropenia by 41% vs. pegfilgrastim alone, based on reduction of profound neutropenia \- Posters presented at the 2020 San Antonio Breast Cancer Symposium NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a g...

    11/29/2020BYSI
    Do Hedge Funds Love BeyondSpring, Inc. (BYSI)?

    How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

    11/25/2020BYSI
    BeyondSpring to Present at Two Upcoming Scientific Conferences in December

    * BeyondSpring to present at the 62nd American Society of Hematology (ASH) Annual Meeting and at the 2020 San Antonio Breast Cancer Symposium NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced a poster presentation about the PROTECTIVE-2 Trial (ClinicalTrials.gov ID: NCT03294577) at the 62nd American Society of Hematology (ASH) Ann...

    11/23/2020BYSI
    BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference

    NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the 2020 Evercore ISI HealthCONx Conference on December 2, 2020. Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer of BeyondSpring will partic...